Related references
Note: Only part of the references are listed.Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample
A. G. Hirsch et al.
ALLERGY (2017)
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Endotype-driven treatment in chronic upper airway diseases
Glynnis De Greve et al.
CLINICAL AND TRANSLATIONAL ALLERGY (2017)
Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement
P. W. Hellings et al.
ALLERGY (2017)
Economics of Chronic Rhinosinusitis
Luke Rudmik
CURRENT ALLERGY AND ASTHMA REPORTS (2017)
Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression
Robert P. Schleimer et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Claus Bachert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers
Peter Tomassen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen- induced early asthmatic responses
Gail M. Gauvreau et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaci et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial
Paul M. O'Byrne et al.
LANCET RESPIRATORY MEDICINE (2016)
Allergic Fungal Rhinosinusitis
Alice E. W. Hoyt et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2016)
A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma
Jeffrey M. Harris et al.
RESPIRATORY RESEARCH (2016)
NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity
D. R. Morales et al.
ALLERGY (2015)
Pharmacological Therapy of Bronchial Asthma: The Role of Biologicals
Sebastian Heck et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2015)
Cost of Adult Chronic Rhinosinusitis: A Systematic Review
Kristine A. Smith et al.
LARYNGOSCOPE (2015)
Identification of chronic rhinosinusitis phenotypes using cluster analysis
Zachary M. Soler et al.
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2015)
Immunopathology of chronic rhinosinusitis
Atsushi Kato
ALLERGOLOGY INTERNATIONAL (2015)
The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: A 3-year prospective observational study
Stephan Vlaminck et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects
J. P. Arm et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production
Gail M. Gauvreau et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs
M. L. Kowalski et al.
ALLERGY (2013)
Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma
William W. Busse et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Chronic rhinosinusitis: an update on current pharmacotherapy
Gwijde F. J. P. M. Adriaensen et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology
Cezmi A. Akdis et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Type 2 innate lymphoid cells control eosinophil homeostasis
Jesse C. Nussbaum et al.
NATURE (2013)
Identification of chronic rhinosinusitis phenotypes using cluster analysis
Tsuguhisa Nakayama et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2012)
Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial
P. Nair et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
J. Bousquet et al.
ALLERGY (2011)
Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN study
D. Hastan et al.
ALLERGY (2011)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Incremental Health Care Utilization and Expenditures for Chronic Rhinosinusitis in the United States
Neil Bhattacharyya
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2011)
Quality of Life in Patients with Chronic Rhinosinusitis
Luke Rudmik et al.
CURRENT ALLERGY AND ASTHMA REPORTS (2011)
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
T. Van Zele et al.
ALLERGY (2006)
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps
Philippe Gevaert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
W Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Share Paper
